FDA panel to review Mallinckrodt application for kidney failure med

As expected, the FDA’s Cardiovascular and Renal Drugs Advisory Committee will conduct a virtual meeting to review and discuss Mallinckrodt’s (MNK +0.8%) marketing application seeking approval to use terlipressin to treat hepatorenal syndrome type 1 (HRS-1), a type of progressive kidney failure in patients with severe liver damage, typically from cirrhosis.

The committee will meet on Wednesday, July 15.

https://seekingalpha.com/news/3589098-fda-advisory-committee-to-review-mallinckrodt-application-for-terlipressin-for-type-of-kidney